SCHEMBL7677799

SCHEMBL7677799

CC1(C)c2c(Cl)cccc2S(=O)(=O)N1CCCl

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA4 P22748 1/20 0.33
CA7 P43166 1/20 0.33
NPC1 O15118 1/20 0.31
LMNA P02545 1/20 0.31
RET P07949 1/20 0.31
GRK5 P34947 1/20 0.31
TYRO3 Q06418 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
ELANE P08246 4/20 0.31
HTT P42858 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7677006 0.81 ELANE (0.32) CA2CA9CA12CA1CA4
SCHEMBL7954706 0.78 ELANE (0.35) CA2CA9CA12ELANEALDH1A1
SCHEMBL7686586 0.75 PKM (0.33) ELANE
SCHEMBL7686476 0.67 GAA (0.35) CA2CA9CA12LMNAELANE
SCHEMBL7684565 0.64 CA12 (0.45) CA2CA9CA12CA1CA4
SCHEMBL23518159 0.59 CA9 (0.41) CA2CA9CA12LMNAELANE
SCHEMBL7679654 0.59 GAA (0.37) CA2CA9CA12ELANEGAA
SCHEMBL11093427 0.58 RET (0.45) CA2CA9CA12CA1CA4
SCHEMBL28322086 0.58 LMNA (0.37) CA2CA9CA12CA1CA4
SCHEMBL7281592 0.57 ELANE (0.58) CA9CA12CA1RETGRK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6346622-B1 ENANTIOMORPHS AND ISOMERS ABBOTT LABORATORIES 2002-02-12 US disclosed
CN-1333685-A Utilisation of I compound for the prophylaxis and therapy of cerebral ischaemia BASF AG (DE) 2002-01-30 CN disclosed
US-6300354-B1 FOR THERAPY OF NEUROLEPTIC DISEASES BASF AKTIENGESELLSCHAFT (DE) 2001-10-09 US disclosed
CN-1277607-A 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-HT1A, 5-HT1b and 5-HT1D) BASF AG (DE) 2000-12-20 CN disclosed